Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine

Brain Res. 2013 Dec 6:1541:92-105. doi: 10.1016/j.brainres.2013.10.011. Epub 2013 Oct 12.

Abstract

Recently, it has been strongly suggested that reciprocal interactions between nitrergic and dopaminergic systems play a crucial role in the control of the nigrostriatal pathway. Degeneration of dopaminergic neurons in the substantia nigra (SN) in Parkinson's disease leads to disturbances in the nitrergic transmission in the basal ganglia. In the present study, we aimed to compare regional distribution of nNOS immunoreactivity and NADPH-diaphorase activity in the SN and subthalamic nucleus (STN) of unilaterally 6-OHDA-lesioned rats treated chronically with l-DOPA (25mg/kg) and the nitric oxide donor, molsidomine (2 or 4mg/kg). Our results showed that degeneration of dopaminergic neurons in the ipsilateral SN resulted in a 25% decrease in the number of nNOS-immunoreactive neurons in that structure and in nNOS protein level determined by Western blot. We also found that nNOS was present in about 70% of all SN neurons. NADPH-d histochemistry did not reveal nNOS activity in the SN of any studied groups. Furthermore, the stereological analysis of the SN volume showed that chronic administration of l-DOPA evoked a hypertrophy of the ipsilateral SN when compared to the contralateral side. Such difference between sides was abolished in the group receiving l-DOPA in combination with molsidomine. Degeneration of the nigrostriatal pathway had no influence on the number of nNOS-ir neurons in the STN. NADPH-histochemistry revealed nNOS activity only in a part of neurons of that structure. Our results make an essential contribution to the research on the role of nitric oxide in the regulation of basal ganglia function.

Keywords: 6-OHDA; 6-hydroxydopamine; CV; Hypertrophy; MFB; NADPH-d; NO; Nitric oxide; PD; Parkinson's disease; SNc; SNr; STN; Substantia nigra; Subthalamic nucleus; TH; cresyl violet; l-DOPA; medial forebrain bundle; mol; molsidomine; nNOS; neuronal nitric oxide synthase; nicotinamide dinucleotide phosphate diaphorase; nitric oxide; substantia nigra pars compacta; substantia nigra pars reticulata; subthalamic nucleus; tyrosine hyroxylase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic Agents / toxicity
  • Animals
  • Antiparkinson Agents / pharmacology
  • Blotting, Western
  • Immunohistochemistry
  • Levodopa / pharmacology
  • Male
  • Molsidomine / pharmacology
  • NADPH Dehydrogenase / metabolism
  • Neurons / enzymology
  • Nitric Oxide Donors / pharmacology
  • Nitric Oxide Synthase Type I / biosynthesis*
  • Oxidopamine / toxicity
  • Parkinsonian Disorders / metabolism*
  • Rats
  • Rats, Wistar
  • Substantia Nigra / drug effects
  • Substantia Nigra / enzymology*
  • Subthalamic Nucleus / drug effects
  • Subthalamic Nucleus / enzymology*

Substances

  • Adrenergic Agents
  • Antiparkinson Agents
  • Nitric Oxide Donors
  • Levodopa
  • Oxidopamine
  • Molsidomine
  • Nitric Oxide Synthase Type I
  • NADPH Dehydrogenase